Empasita

Description

Empasita (Empagliflozin 10mg Sitagliptin 50mg)Empasita– Empagliflozin/ Sitagliptin
•EMPASITA® a fixed combination of empagliflozin 10mg – SGLT2 inhibitor and
Sitagliptin 50mg – DPP–4 inhibitor
Sitagliptin
•Enhances postprandial insulin secretion and suppresses glucagon secretion thus
playing a vital role in glucose homeostasis.
•Stimulates insulin secretion in a glucose–dependent fashion and inhibit glucagon
secretion, thus minimizing hypoglycaemia and improving glycemic control.
•is weight–neutral.
•Empasita provides effective control of hyperglycaemia through
complementary mechanism, without the risk of hypoglycaemia or weight gain
•Empasita not only improves glycaemic control but also has favourable impact on
weight, blood pressure, dyslipidaemia, cardiovascular, and renal outcomes.
•Empasita is ideal for patients who cannot tolerate metformin.